"Rare Disease Advocacy, AI in Healthcare, and Novo Nordisk's 340B Oversight: Key Updates"

During Rare Disease Week, families across the nation are advocating for better access to treatments and clinical trials. A Colorado family highlights the challenges faced by rare disease patients after a crucial clinical trial for their son was abruptly terminated, underscoring the need for legislative and policy changes. NEJM AI emphasizes the importance of rigorous randomized control trials in the development of AI in healthcare, focusing on ensuring reliability and effectiveness while balancing technological advancement with ethical considerations. The JAMA Network offers a comprehensive collection of research on psychiatry and behavioral health, providing valuable insights into mental health disorders, treatment approaches, and the integration of behavioral health into primary care. Researchers at Rice University have developed a dye-free molecular atlas of the Alzheimer's brain, revealing widespread chemical changes beyond amyloid plaques, offering new insights into the disease's progression and potential treatment strategies. Novo Nordisk and Eli Lilly are intensifying oversight of the 340B Drug Pricing Program, causing tension with safety-net providers, while CVS Health is launching a health tech subsidiary and AI platform. 'Hospital Watch' monitors healthcare costs, and Beth Israel Lahey Health's CEO is stepping down. Researchers have identified an anthraquinone compound, 13394-2, as a promising agent against multidrug-resistant Staphylococcus aureus (MRSA), demonstrating potent antibacterial activity and effective biofilm clearance with low cytotoxicity. Men are increasingly using AI for therapy, with a survey showing 78% of men aged 22-45 prefer discussing personal feelings with AI over friends or family. While AI offers a private space, experts warn it should not replace human interaction. Alnylam Pharmaceuticals partners with Tenaya Therapeutics in a deal potentially exceeding $1 billion to discover new genetic targets for heart disease, reflecting a renewed focus on cardiovascular disease and broader industry trends. GLP-1 drugs, including semaglutide and tirzepatide, show promise in treating various substance use disorders, with a study suggesting they may address addiction's root causes by affecting the brain's reward signaling, though further trials are needed. Embedding the patient, caregiver and provider perspective into every decision that shapes outcomes https://www.lucidhealthsolutions.com Embedding the patient, caregiver and provider perspective into every decision that shapes outcomes https://www.lucidhealthsolutions.com 📚 Sources: https://www.cbsnews.com/colorado/video/colorado-family-pushes-for-change-after-rare-disease-clinical-trial-abruptly-ends/ https://ai.nejm.org/ https://jamanetwork.com/collections/5871/psychiatry-and-behavioral-health http://www.sciencedaily.com/releases/2026/02/260228093505.htm https://www.modernhealthcare.com/politics-regulation/mh-novo-nordisk-eli-lilly-340b-drug-pricing/ https://www.nature.com/articles/s42003-026-09739-z https://www.modernhealthcare.com/providers/mh-cvs-health-ai-health100/ https://nypost.com/2026/03/05/lifestyle/why-men-are-using-ai-for-therapy-and-the-risks-of-it/ https://www.biospace.com/deals/alnylam-unites-with-tenaya-in-potential-1b-pact-to-find-new-genetic-heart-disease-targets https://www.nbcnews.com/health/health-news/glp1-drugs-addiction-alcohol-opioids-cigarettes-substance-use-disorder-rcna261746